Physician profile
Frances L Wise
NPI 1992855902
$1,657.53
in general payments reported to CMS, 2019-2025
18 companies · $156 in 2025
The $156 reported for 2025 was more than what a typical Acute Care (Nurse Practitioner) provider received nationally (typical 2025 total: $151).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $175 · 2022: $298 · 2023: $563 · 2024: $466 · 2025: $156.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,185.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,185.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ani Pharmaceuticals, INC. | $298.99 | 2022-2024 | Purified Cortrophin Gel |
| Vifor Pharma, INC. | $178.74 | 2021-2024 | Veltassa |
| Bayer Healthcare Pharmaceuticals INC. | $171.67 | 2021-2024 | |
| Travere Therapeutics, INC. | $160.79 | 2023-2025 | Filspari |
| Amgen INC. | $141.89 | 2021-2024 | Krystexxa, Tavneos |
| Akebia Therapeutics INC | $112.67 | 2021-2023 | Auryxia |
| Glaxosmithkline, LLC. | $83.07 | 2021-2024 | Jesduvroq |
| Fresenius USA Marketing, INC. | $78.86 | 2023 | Korsuva |
| Astrazeneca Pharmaceuticals LP | $70.24 | 2021-2023 | Farxiga |
| Novartis Pharmaceuticals Corporation | $66.10 | 2025 | |
| Otsuka America Pharmaceutical, INC. | $63.82 | 2022-2024 | Jynarque |
| Mallinckrodt Hospital Products INC. | $56.32 | 2023 | Acthar, Terlivaz |
| Calliditas Therapeutics US INC. | $49.88 | 2024 | |
| Horizon Therapeutics Plc | $41.63 | 2023 | Krystexxa |
| Novo Nordisk INC | $27.89 | 2024 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $23.37 | 2024 | Ibsrela |
| Hikma Pharmaceuticals USA | $15.93 | 2023 | Mitigare |
| Lilly USA, LLC | $15.67 | 2024 | Jardiance |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Frances Wise listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.